{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:26:43Z","timestamp":1793467603006,"version":"4.5.0"},"reference-count":35,"publisher":"Korean Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["02-2022-0037"],"award-info":[{"award-number":["02-2022-0037"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2025,4,15]]},"abstract":"<jats:p>Purpose Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain.Materials and Methods We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021.Results Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age \u2265 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores \u2265 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding.Conclusion Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.<\/jats:p>","DOI":"10.4143\/crt.2024.738","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T05:42:16Z","timestamp":1726810936000},"page":"612-620","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients"],"prefix":"10.4143","volume":"57","author":[{"given":"Ji Yun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woochan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongmin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716614"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-460154"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3099-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7326\/m17-0028"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5387-9"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.07.062"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153783"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238956"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-591610"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.34.5298"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-429134"},{"key":"ref12","first-page":"1612","volume-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","author":"Steffel","year":"2021"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000665"},{"key":"ref14","first-page":"e545","volume-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","author":"Stevens","year":"2021"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00566-5"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01279-1"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/19371910903070333"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3164-x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571232"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000918"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-125328"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.04.008"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-339002"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12053"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.85"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2330-2"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003628"},{"key":"ref30","first-page":"104","volume-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society","author":"January","year":"2019"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26008"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13721"},{"key":"ref33","first-page":"18","volume-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","author":"Kaifie","year":"2016"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2022.10.007"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.738","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2024-738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T23:02:06Z","timestamp":1747263726000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2024.738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2024.738","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2024-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}